ADMA Biologics Inc (ADMA) Financial Statements (2026 and earlier)

Company Profile

Business Address C/O ADMA BIOLOGICS, INC.
RAMSEY, NJ 07446
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments90,28571,625103,14786,70788,24445,325
Cash and cash equivalent90,28571,625103,14786,70788,24445,325
Receivables109,72699,41249,99950,14030,11349,621
Inventory, net of allowances, customer advances and progress billings191,464172,188170,235171,801179,810177,732
Inventory191,464172,188170,235171,801179,810177,732
Other undisclosed current assets8,0888,5898,0299,5455,5243,741
Total current assets:399,563351,814331,410318,193303,691276,419
Noncurrent Assets
Operating lease, right-of-use asset8,9618,0208,6348,8979,1529,397
Property, plant and equipment57,50157,71054,70753,69454,32655,317
Intangible assets, net (including goodwill)4,0573,9823,9904,0154,0093,851
Goodwill3,5303,5303,5303,5303,5303,530
Intangible assets, net (excluding goodwill)527452460485479321
Deferred income tax assets79,23580,85584,280   
Other undisclosed noncurrent assets9,0638,1885,6575,8195,2215,891
Total noncurrent assets:158,817158,755157,26872,42572,70874,456
TOTAL ASSETS:558,380510,569488,678390,618376,399350,875
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities69,10946,85749,19938,24337,07933,218
Accounts payable29,76920,60720,21916,02014,17917,186
Accrued liabilities39,34026,25028,98022,22322,90016,032
Deferred revenue 1431431431431,1301,118
Debt      
Other undisclosed current liabilities5,6896,4986,2006,5055,96818,752
Total current liabilities:74,94153,49855,54244,89144,17753,088
Noncurrent Liabilities
Long-term debt and lease obligation73,39772,52772,337101,326131,074130,847
Long-term debt, excluding current maturities73,39772,52772,337101,326131,074130,847
Liabilities, other than long-term debt10,7799,81210,46810,82311,19111,546
Deferred revenue1,4761,5121,5471,5831,6191,654
Other liabilities22360375390405
Operating lease, liability9,3018,2988,5618,8659,1829,487
Other undisclosed noncurrent liabilities 9381,3131,3131,6881,6881,688
Total noncurrent liabilities:85,11483,65284,118113,837143,953144,081
Total liabilities:160,055137,150139,660158,728188,130197,169
Equity
Equity, attributable to parent398,325373,419349,018231,890188,269153,706
Common stock242424242323
Treasury stock, value(15,148)     
Additional paid in capital660,909655,074657,577652,345644,634642,133
Accumulated deficit(247,460)(281,679)(308,583)(420,479)(456,388)(488,450)
Total equity:398,325373,419349,018231,890188,269153,706
TOTAL LIABILITIES AND EQUITY:558,380510,569488,678390,618376,399350,875

Income Statement (P&L) ($ in thousands)

9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
Revenues121,984114,802117,549119,839107,19181,875
Cost of revenue(54,757)(53,705)(54,216)(60,180)(49,738)(42,767)
Gross profit:67,22761,09763,33359,65957,45339,108
Operating expenses(24,429)(26,216)(25,010)(20,021)(18,252)(17,287)
Operating income:42,79834,88138,32339,63839,20121,821
Nonoperating expense(2,701)(1,431)(3,610)(2,889)(3,350)(3,420)
Investment income, nonoperating400608598666449384
Interest and debt expense(1,159)(1,975)9,808(3,499)(3,783)(3,769)
Income from continuing operations before equity method investments, income taxes:38,93831,47544,52133,25032,06814,632
Other undisclosed income (loss) from continuing operations before income taxes1,1591,975(9,808)3,4993,7833,769
Income from continuing operations before income taxes:40,09733,45034,71336,74935,85118,401
Income tax expense (benefit)(5,878)(6,546)77,183(840)(3,789)(595)
Net income available to common stockholders, diluted:34,21926,904111,89635,90932,06217,806

Comprehensive Income ($ in thousands)

9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
Net income:34,21926,904111,89635,90932,06217,806
Comprehensive income, net of tax, attributable to parent:34,21926,904111,89635,90932,06217,806

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: